349 related articles for article (PubMed ID: 15926759)
1. Total costs of IBS: employer and managed care perspective.
Cash B; Sullivan S; Barghout V
Am J Manag Care; 2005 Apr; 11(1 Suppl):S7-16. PubMed ID: 15926759
[TBL] [Abstract][Full Text] [Related]
2. Impairment in work productivity and health-related quality of life in patients with IBS.
Dean BB; Aguilar D; Barghout V; Kahler KH; Frech F; Groves D; Ofman JJ
Am J Manag Care; 2005 Apr; 11(1 Suppl):S17-26. PubMed ID: 15926760
[TBL] [Abstract][Full Text] [Related]
3. The economic consequences of irritable bowel syndrome: a US employer perspective.
Leong SA; Barghout V; Birnbaum HG; Thibeault CE; Ben-Hamadi R; Frech F; Ofman JJ
Arch Intern Med; 2003 Apr; 163(8):929-35. PubMed ID: 12719202
[TBL] [Abstract][Full Text] [Related]
4. Tegaserod treatment for IBS: a model of indirect costs.
Smith DG; Barghout V; Kahler KH
Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763
[TBL] [Abstract][Full Text] [Related]
5. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective.
Vicente-Herrero T; Burke TA; Laínez MJ
Curr Med Res Opin; 2004 Nov; 20(11):1805-14. PubMed ID: 15537481
[TBL] [Abstract][Full Text] [Related]
6. [Irritable bowel syndrome: epidemiology/economic burden].
Dapoigny M
Gastroenterol Clin Biol; 2009 Feb; 33 Suppl 1():S3-8. PubMed ID: 19303536
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of irritable bowel syndrome: what does the future hold?
Cash B
Am J Manag Care; 2005 Apr; 11(1 Suppl):S4-6. PubMed ID: 15926758
[No Abstract] [Full Text] [Related]
8. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
Paré P; Gray J; Lam S; Balshaw R; Khorasheh S; Barbeau M; Kelly S; McBurney CR
Clin Ther; 2006 Oct; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective.
Lamb CE; Ratner PH; Johnson CE; Ambegaonkar AJ; Joshi AV; Day D; Sampson N; Eng B
Curr Med Res Opin; 2006 Jun; 22(6):1203-10. PubMed ID: 16846553
[TBL] [Abstract][Full Text] [Related]
10. The spectrum of irritable bowel syndrome: A clinical review.
Gilkin RJ
Clin Ther; 2005 Nov; 27(11):1696-709. PubMed ID: 16368443
[TBL] [Abstract][Full Text] [Related]
11. Economic burden of irritable bowel syndrome in China.
Zhang F; Xiang W; Li CY; Li SC
World J Gastroenterol; 2016 Dec; 22(47):10450-10460. PubMed ID: 28058026
[TBL] [Abstract][Full Text] [Related]
12. Modeling the impact of enhanced depression treatment on workplace functioning and costs: a cost-benefit approach.
Lo Sasso AT; Rost K; Beck A
Med Care; 2006 Apr; 44(4):352-8. PubMed ID: 16565636
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea.
Buono JL; Carson RT; Flores NM
Health Qual Life Outcomes; 2017 Feb; 15(1):35. PubMed ID: 28196491
[TBL] [Abstract][Full Text] [Related]
14. Indirect cost of ischemic heart disease to employers.
Guico-Pabia CJ; Murray JF; Teutsch SM; Wertheimer AI; Berger ML
Am J Manag Care; 2001 Jan; 7(1):27-34. PubMed ID: 11209448
[TBL] [Abstract][Full Text] [Related]
15. Budget impact of tegaserod on a managed care organization formulary.
Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM
Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome.
DiBonaventura M; Sun SX; Bolge SC; Wagner JS; Mody R
Curr Med Res Opin; 2011 Nov; 27(11):2213-22. PubMed ID: 21951105
[TBL] [Abstract][Full Text] [Related]
17. Absenteeism among employees with irritable bowel syndrome.
Zacker C; Chawla AJ; Wang S; Albers LA
Manag Care Interface; 2004 May; 17(5):28-32. PubMed ID: 15217162
[TBL] [Abstract][Full Text] [Related]
18. How does comorbidity affect cost of health care in patients with irritable bowel syndrome? A cohort study in general practice.
Johansson PA; Farup PG; Bracco A; Vandvik PO
BMC Gastroenterol; 2010 Mar; 10():31. PubMed ID: 20233451
[TBL] [Abstract][Full Text] [Related]
19. The burden of illness associated with renal cell carcinoma in the United States.
Lang K; Danchenko N; Gondek K; Schwartz B; Thompson D
Urol Oncol; 2007; 25(5):368-75. PubMed ID: 17826652
[TBL] [Abstract][Full Text] [Related]
20. Economic cost of Guillain-Barré syndrome in the United States.
Frenzen PD
Neurology; 2008 Jul; 71(1):21-7. PubMed ID: 18591502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
